(Q36953492)

17 August 2017

Intratumoral immunocytokine treatment results in enhanced antitumor effects (English)

1 reference

17 August 2017

8

Andrew Raubitschek

0 references

author name string

Erik E Johnson

1

1 reference

17 August 2017

Hillary D Lum

2

1 reference

17 August 2017

Alexander L Rakhmilevich

3

1 reference

17 August 2017

Brian E Schmidt

4

1 reference

17 August 2017

Meghan Furlong

5

1 reference

17 August 2017

Ilia N Buhtoiarov

6

1 reference

17 August 2017

Jacquelyn A Hank

7

1 reference

17 August 2017

Andrew Raubitschek

8

1 reference

17 August 2017

David Colcher

9

1 reference

17 August 2017

Ralph A Reisfeld

10

1 reference

17 August 2017

Stephen D Gillies

11

1 reference

17 August 2017

Paul M Sondel

12

1 reference

17 August 2017

26 April 2008

1 reference

Cancer Immunology, Immunotherapy

17 August 2017

1 reference

17 August 2017

57

1 reference

17 August 2017

12

1 reference

17 August 2017

1891-1902

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-008-0519-0

17 August 2017

0 references

cites work

In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Antibody-directed, effector cell-mediated tumor destruction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574976

Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein

4 September 2018

1 reference

12 December 2020

Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy

1 reference

12 December 2020

Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents

1 reference

12 December 2020

In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2

1 reference

12 December 2020

Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors

1 reference

12 December 2020

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2

1 reference

12 December 2020

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

12 December 2020

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

12 December 2020

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

12 December 2020

Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma

1 reference

12 December 2020

3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study

1 reference

12 December 2020

Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin

1 reference

12 December 2020

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

1 reference

12 December 2020

Immunocytokines: a promising approach to cancer immunotherapy

1 reference

12 December 2020

Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors

1 reference

12 December 2020

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

1 reference

12 December 2020

Intra-tumoral injection of doxorubicin (adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects

1 reference

12 December 2020

10.1007/S00262-008-0519-0

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

1 reference